Background-In patients with percutaneous device implantation for closure of patent foramen ovale (PFO), a 10% incidence of new or worsened aortic regurgitation within 12 months has been reported with echocardiography. Cardiac magnetic resonance imaging is a powerful noninvasive tool to quantify volume and fraction of valve insufficiencies. We studied the acute and long-term impact of percutaneous device implantation for PFO closure on valve insufficiencies in cardiac magnetic resonance imaging. Methods and Results-Sequential cardiac magnetic resonance imaging studies were performed in 102 patients with cryptogenic ischemic events. Cardiac magnetic resonance imaging was performed before PFO closure, the day after device implantation, and at 12 months of follow-up. There was no difference in volumetric and hemodynamic parameters before PFO closure compared with 12 months of follow-up. With a cutoff for relevant regurgitation fraction of 5%, there were no statistically significant differences in regurgitation fraction of the semilunar and atrioventricular valves. The median fraction of aortic valve insufficiency was 3.9% (interquartile range [IQR] 2.0% to 5.1%) before PFO closure, 5.4% (IQR 4.1% to 5.9%) after device implantation, and 4.3% (IQR 3.3% to 6.0%) at 12 months of follow-up. The size and type of the occluder had no impact on aortic valve insufficiency. Median regurgitation fraction for the pulmonary valve was 3.6% (IQR 2.4% to 6.7%) before intervention, 7.3% (IQR 5.1% to 8.2%) after occluder implantation and 5.8% (IQR 4.8% to 7.4%) at 12 months of follow-up. Values for the mitral valve were 3.1% (IQR 1.4% to 6.0%), 5.5% (IQR 3.5% to 7.3%), and 3.8% (IQR 1.5% to 7.9%) and for the tricuspid valve were 5.4% (IQR 0.1% to 8.8%), 5.8% (IQR 1.4% to 9.2%), and 6.0% (IQR 1.1% to 8.4%), respectively. Conclusions-Percutaneous PFO closure with device implantation has no impact on valve insufficiencies as determined by cardiac magnetic resonance imaging. (Circulation. 2009;119:3002-3008.)
W ith increasing use of percutaneous transcatheter device implantation for closure of patent foramen ovale (PFO) in patients with cryptogenic ischemic events, 1 the question of long-term efficacy and safety has been raised. [1] [2] [3] [4] Efficacy has been addressed by evidence of PFO closure determined in transthoracic echocardiography, transesophageal echocardiography (TEE), [3] [4] [5] and cardiac magnetic resonance imaging (CMRI). 5, 6 During long-term follow-up, recurrence of ischemic events such as stroke, transient ischemic event, or peripheral emboli has been analyzed. 2, 3, 7 With respect to safety complications during device implantation, 2 atrial erosion 8 and thrombus formation on the device 4 were the focus. Very recently with sequential echocardiographic studies, a new long-term safety aspect has been addressed. 9 There was a 10% incidence of new or worsened aortic regurgitation within a 12-month period. Although echocardiography is the currently preferred approach for detection of valve insufficiencies, quantification of regurgitation is more accurate with CMRI.
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CMRI is a noninvasive powerful imaging technique providing detailed information on cardiac anatomy, function, and hemodynamic values. 5,10 -14 Although we have shown that present CMRI technique is inferior to TEE in detection of contrast-enhanced right-to-left shunting and identification of atrial septal aneurysm, 5 we could also demonstrate that routine CMRI after transcatheter closure of PFO is feasible and safe. 5, 15, 16 Velocity mapping CMRI is a well-validated approach to directly quantify the severity of regurgitant semilunar valves. [17] [18] [19] [20] [21] [22] In combination with ventricular volumetric data, insufficiencies of the atrioventricular valves can be quantified with excellent reproducibility. 17, [22] [23] [24] [25] We studied the acute and long-term impact of percutaneous PFO closure by device implantation on valve insufficiencies in CMRI.
Methods

Patients
Patients with percutaneous PFO closure were studied with sequential CMRI for potential impact of device implantation on valve insufficiencies and volumetric and hemodynamic parameters. Indication for PFO closure was based on cryptogenic ischemic events as defined elsewhere 5 and evidence of a PFO with contrast-enhanced interatrial right-to-left-shunt at rest or during Valsalva provocation as seen in transesophageal echocardiography. Diagnostic work-up before PFO closure included 12-lead ECG, Holter monitoring, Doppler sonography, transthoracic echocardiography, TEE, and coagulation blood tests. An atrial septal aneurysm (ASA) was defined as an excursion of the atrial septum Ͼ10 mm. 26 All patients were in sinus rhythm, and there was no indication for oral anticoagulation because of other disorders. The study was ethically approved. All patients gave their written informed consent for PFO closure as well as CMRI studies.
Magnetic Resonance Imaging
CMRI was performed before PFO closure. To assess acute changes after device implantation, CMRI was repeated the day after PFO closure, and for evaluation of chronic changes, CMRI was performed again after 12 months. Patients with all 3 CMRI studies were analyzed to allow evaluation of the acute and chronic impact of device implantation on valve insufficiencies and hemodynamic and volumetric parameters. CMRI was done on a 1.5T Intera CV whole body MR Scanner (Philips Medical Systems), equipped with a high-performance gradient system (maximal gradient strength 30 mT/m, maximal slew rate 150 mT/m · sec). All data were acquired using a dedicated 5-element cardiac phased-array coil. To determine left and right ventricular function, a retrospective ECG-gated segmented k-space balanced turbo-field echo sequence (steady-state free precession) without view sharing was used in short axis views perpendicular to the true heart axis. Slice thickness was 10 mm with no gap. For whole coverage of right and left ventricle, slice number was individually adjusted. Depending on the required field of view, the spatial resolution was between 1.7ϫ1.8 mm and 2.3ϫ1.8 mm in-plane. The following parameters were used: echo time 1.7 ms, repetition time 3.4 ms, parallel imaging (sensitivity encoding) factor 2. Flow measurements in the pulmonary artery and aorta were performed by means of a conventional-phase contrast technique with retrospective gating with free-breathing (field of view 300 mm, slice thickness 6 mm). Scans were planned in the transverse plane crossing the aorta or pulmonary artery perpendicular to the direction of the vessel. Slice position was optimized in 2 additional long-axis scans to account for movement of pulmonary and aortic valve over the cardiac cycle. Default flow velocity was set to 100 cm/sec for pulmonary flow and to 150 cm/sec for aortic flow, with individual adjustment and scan repetition in case of aliasing.
Left and right ventricular function and volumetry as well as quantification of flow measurements were carried out on an EasyVision workstation (Philips Medical Systems). End-diastolic and systolic ventricular volumes were determined by manual segmentation of endocardial borders, including papillary muscles, as described before. 10, 14 Functional parameters derived from volumetric data were calculated as follows: ventricular stroke volume (mL) ϭ end-diastolic volume (mL) Ϫ systolic volume (mL). Heart minute volume (mL/min) ϭ stroke volume (mL) ϫ heart rate (bpm).
Aortic and pulmonary flows were measured by automatic segmentation of the vessel border. In each phase, segmentation was checked and manually corrected if not appropriate. The aortic and pulmonary flow volumes, subdivided in forward and backward flows (insufficiency volume), were automatically supplied by the software (Easy Vision workstation, Philips Medical Systems). The regurgitation fraction was calculated as the proportion of backward flow volume on total flow volume for the aortic and pulmonary valves. Mitral insufficiency volume was calculated as left ventricular stroke volume derived from left ventricular volumetry minus aortic total flow volume. Mitral regurgitation fraction was defined as mitral insufficiency volume divided by left ventricular stroke volume. Tricuspid insufficiency volume was calculated as right ventricular stroke volume derived from right ventricular volumetry minus pulmonary total flow volume. Tricuspid insufficiency fraction was defined as tricuspid insufficiency volume divided by right ventricular stroke volume. The quantification of valve insufficiencies using phase-contrast CMRI is a class I indication according to the consensus panel report. 25 This recommendation is based on welldescribed and validated techniques for quantitative assessment, which are associated with a high reproducibility. [17] [18] [19] [20] [21] [22] [23] [24] [25] We carefully performed shunt quantification according to the method described in detail by Araoz et al. 27 using left and right ventricular volumetry as well as flow measurements. Cutoff for detectable shunts by CMRI was set to Ͼ5% of cardiac output.
PFO Closure
The device for PFO closure was implanted in the catheter laboratory under fluoroscopic and TEE guidance as described elsewhere. 5 The following occluders were implanted: Premere PFO Closure System (St. Jude Medical) Cardia PFO occluder, Cardia Intrasept PFO occluder (Cardia), Amplatzer PFO occluder, Amplatzer septal occluder, and Amplatzer multi-fenestrated septal occluder (cribriform) (AGA Medical Corporation). Procedures were performed with local anesthesia and mild facultative sedation if necessary. Patients received a combined antiplatelet therapy with 100 mg of acetylsalicylic acid and 75 mg of clopidogrel sulfate per day for 3 to 6 months.
Statistics
Categorical parameters are presented as counts and percentages. Continuous variables were tested for normal distribution by use of the Shapiro-Wilks test. Data with normal distribution are presented as meanϮSD; nonnormally distributed data are presented as median and interquartile range (IQR). Nonnormally distributed continuous variables for 2 groups were compared using the Mann-Whitney U test, and comparison of proportions with the 2 test. For comparison of continuous parameters between the three CMRI studies, the Friedman ANOVA test was applied. For comparison of parameters before PFO closure with those at 12 months, the Wilcoxon signedrank test was used. The Bonferroni correction was applied to account for type I error due to multiple testing. A P value Ͻ0.001 was considered to be statistically significant. Statistical analysis was done with Statistica release 7.1 (StatSoft Inc).
Results
Patients
Of 129 patients with a CMRI study before PFO closure, 102 patients underwent repeat CMRI the day after device implan- 
Cardiac Magnetic Resonance Imaging
CMRI at 12 months of follow-up was performed a median of 367 days (range 321 to 399 days) after PFO closure. There were no adverse events or side effects of CMRI studies. Volumetric left and right ventricular parameters are detailed in Table 2 . Heart rate at CMRI study 1 day after PFO closure was significantly higher compared with the other 2 CMRI studies. All patients were in sinus rhythm. Comparing the parameters between all 3 CMRI studies, significant differences were observed with respect to left ventricular and right ventricular end-diastolic and end-systolic volumes and volume indexes. There were no statistical significant differences comparing the CMRI parameters before PFO with those obtained at 12 months of follow-up.
The impact of PFO closure on valve insufficiencies is detailed in Table 3 . No cutoff value was defined to allow detection of even minor changes. There were no statistical significant differences with respect to percentage as well as absolute volume of valve insufficiencies for the aortic, mitral, and tricuspid valve in comparison of all 3 CMRI studies. There was a statistically significant increase in percentage and absolute volume of pulmonary valve insufficiency (PϽ0.001). The absolute mean volume increased from 1.5 mL to 2.0 mL per cardiac cycle within 12 months and was correlated with an increase in mean fraction of pulmonary valve regurgitation from 1.5% up to 2.2%. Similar results were obtained analyzing the differences of percentage and volume of valve insufficiencies before PFO closure with 12 months of follow-up. There were no relevant differences in regurgitation fraction of all 4 valves at every CMRI study between patients treated with the Cardia device and patients having received an Amplatzer occluder (Table 4 ). To evaluate more relevant insufficiencies in CMRI, we selected a cutoff value of 5%. Only patients with at least 1 regurgitation fraction above this cutoff were analyzed. There were 26 patients with a Ͼ5% fraction of aortic valve insufficiency in at least 1 of the 3 CMRI studies. The median fraction of aortic valve insufficiency was 3.9% (IQR 2.0% to 5.1%) before PFO closure, 5.4% (IQR 4.1% to 5.9%) after device implantation, and 4.3% (IQR 3.3% to 6.0%) at 12 months of follow-up. Twelve of 92 patients with an aortic regurgitation fraction Ͻ5% before PFO closure showed a regurgitation fraction Ͼ5% after device implantation. In 2 of the 12 patients, regurgitation fraction remained Ͼ5% at 12 months of follow-up (6.0% and 9.8%).
An insufficiency of Ͼ5% in at least 1 CMRI study was seen at the pulmonary valve in 11 patients, at the mitral valve in 45 patients and at the tricuspid valve in 53 patients. The median fraction of insufficiency for the pulmonary valve before PFO closure was 3.6% (IQR 2.4% to 6.7%), after occluder implantation was 7.3% (IQR 5.1% to 8.2%), and at 12 months of follow-up was 5.8% (IQR 4.8% to 7.4%). Values for the mitral valve were 3.1% (IQR 1.4% to 6.0%), 5.5% (IQR 3.5% to 7.3%), and 3.8% (IQR 1.5% to 7.9%), respectively, and for the tricuspid valve were 5.4% (IQR 0.1% to 8.8%), 5.8% (IQR 1.4% to 9.2%), and 6.0% (IQR 1.1% to 8.4%), respectively. There were no statistically significant differences for changes in percentage of insufficiency for the semilunar and atrioventricular valves. Individual changes in percentage of valve insufficiencies are detailed in the Figure. To analyze the possible impact of device size on aortic regurgitation fraction, we compared the results of 37 patients treated with devices Յ25 mm in size with 65 patients treated with devices Ͼ25 mm. No differences were observed with respect to aortic regurgitation fraction before PFO closure ( There was no statistically significant difference in the size of the implanted occluders with 28 mm (IQR 25 to 34 mm) in patients without ASA and 32 mm (IQR 25 to 35 mm) mm in patients with ASA (Pϭ0.33). Of 92 patients with aortic regurgitation fraction Ͻ5% at the first CMRI study, 58 patients had an ASA and 34 did not. An aortic regurgitation fraction Ͼ5% was observed in 1 of 34 patients (2.9%) without ASA and in 11 of 58 patients (19.0%; Pϭ0.028) with ASA. At the 12-months CMRI, an aortic regurgitation fraction Ͼ5% remained in 2 patients with ASA. Median aortic regurgitation fraction in patients without as compared with patients with ASA was 1.6% (IQR 0.7% to 2.6%) versus 2.3% (IQR 1.0% to 4.1%) (Pϭ0.028) before PFO closure, 1.8% (IQR 1.2% to 3.5%) versus 3.0% (IQR 1.8% to 4.6%) (Pϭ0.013) after device implantation, and 2.3% (IQR 1.4% to 3.8%) versus 2.6% (IQR 1.6% to 4.1%) (Pϭ0.421) at 12 months of follow-up.
By careful shunt quantification, we were able to calculate systemic left-to-right shunts before intervention in 24 of 102 patients (23.5%) with a mean shunt fraction of 7.5Ϯ2.3% (range 5.0% to 12.6%) of cardiac output. After device implantation, a remaining left-to-right shunt was observed in 6 of 24 patients (25.0%) with a mean shunt fraction of 6.8Ϯ1.4% (range 5.2% to 9.2%), which disappeared until 12 months' CMRI study.
Discussion
In this prospective study including 102 patients with 3 sequential CMRI studies, we were able to demonstrate that percutaneous device implantation for PFO closure has no impact on volume and fraction of insufficiencies of the semilunar and atrioventricular valves measured in CMRI.
Studies on long-term outcome after percutaneous PFO closure have been mainly focused on clinical events, 2,3,7 erosion of atrial wall, 8 or thrombus formation on the device. 4 There is one article studying the impact of device implantation in atrial septal defects (ASD) and PFO on changes in valve regurgitations determined by echocardiography. 9 In that study, safety concerns have been raised with respect to an increase in mild and moderate aortic regurgitation within a follow-up period of 12 months. In 170 patients, PFO closure was performed predominantly with the Cardia device (nϭ167) and in only 3 cases with Amplatzer septal occluder. With quite similar baseline characteristics and device sizes compared with our trial, a 10% (nϭ17) rate of newly developed or worsened aortic regurgitation was observed. No significant changes on function of other heart valves were found. Discussed mechanisms for occurrence of aortic regurgitation were changes in the septal geometry and traction on the aortic valve by endothelialization and tissue overgrowing of the device. No quantification of volumes and fractions of regurgitations were reported. We have shown that CMRI after transcatheter device implantation is feasible and safe. 5, 13, 15, 16 Velocity-encoding cine CMRI in combination with right and left ventricular volumetry allows quantification of volume and fraction of insufficiencies of the semilunar and atrioventricular valves with good reproducibility. [17] [18] [19] [20] [21] [22] [23] [24] [25] Without a cutoff value for relevant valve regurgitation, no statistically significant differences were observed for the aortic, mitral, and tricuspid valves. In contrast, absolute volume and percentage of pulmonary valve insufficiency differed between all 3 CMRI studies. Similar results were obtained comparing only the CMRI study before device implantation and at 12 months of follow-up. The change in mean absolute regurgitation volume of the pulmonary valve was from 1.5 mL up to 2.0 mL. Also statistically significantly different, the absolute difference in mean regurgitation volume of 0.5 mL has clinically no relevance. Earlier studies have discussed that fraction and volume of regurgitation can be calculated in CMRI with an error of Ϸ5%. With a cutoff value of 5% for relevant valve regurgitation, no differences were observed for the semilunar and atrioventricular valves. Furthermore, we were able to demonstrate that aortic insufficiency was not influenced by type (Amplatzer or Cardia occluders) or size of the device. The incidence of a new aortic insufficiency with a regurgitation fraction Ͼ5% after occluder implantation was significantly higher in patients with ASA as compared with patients without ASA, which might be influenced by the significantly higher aortic regurgitation fraction before device implantation in patients with ASA compared with patients without ASA. Nevertheless, fraction of aortic regurgitation did not differ at 12-month CMRI, and no long-term sequelae were observed.
There are meaningful differences between our study and the data reported by Schoen et al. 9 We focused on patients with PFO after cryptogenic ischemic events and studied the patients with CMRI before and after device implantation as well as at 12 months of follow-up. In contrast, Schoen et al. combined patients with PFO and ASD and used serial TEE and transthoracic echocardiography for evaluation of aortic regurgitation. 9 Although PFO size was not reported, the implantation of devices with the same mean size for closure of PFO and ASD suggests the use of rather larger devices for PFO closure. A larger device in relation to a smaller PFO could put more stress on the aortic root. Although assessment of aortic regurgitation was carried out according to the American Heart Association guidelines, 28 they did not include measurement of vena contracta or proximal isovelocity surface area, which are more robust parameters compared with jet width in relation to outflow tract or pressure half-time, 29 not allowing quantification of regurgitant volume. Furthermore, the aortic valve has 3 semilunar cusps. The competent closure of the aortic valve is based on their shape and array, which is characterized by an adaptation of the borders of the cusps over several millimeters to fully occlude the outflow tract and prevent backflow into the ventricle during diastole. A shrinking process based on tissue growth due to an occluder in the atrial septum with subsequent traction on the noncoronary cusp via the aortic root is in principle possible, but has to be a pronounced effect to overcome the complete adaptation of the cusp borders.
A relevant aortic regurgitation would increase left ventricular end-diastolic, end-systolic, and stroke volume while decreasing the ejection fraction-at least during long-term follow-up. No differences in volumetric parameters were found before PFO closure to 12 months of follow-up. The differences in volumetric parameters between the CMRI studies before device implantation and the day after PFO closure may be explained by the higher heart rate, which could reflect a reaction to the new implanted PFO device triggering an increased heart rate. Another reason may be blood loss during device implantation during careful backward bleeding after positioning of the long delivery sheath, although the amount of this blood loss is usually very limited. Nevertheless, volumetric, hemodynamic, and functional parameters did not differ in CMRI before PFO closure and at 12 months of follow-up.
Limitations
The study results are restricted to patients with PFO and do not apply to patients with ASD. Results in ASD patients with use of larger devices may be different. Furthermore, our results cannot be applied to the use of PFO devices in general because we implanted predominantly Cardia and Amplatzer occluders in this CMRI study. Quantification of valve insufficiencies with CMRI is associated with an error of Ϸ5%. Nevertheless, CMRI is the best noninvasive approach to quantify valve insufficiency volumes and to calculate regurgitation fraction. 25
Conclusions
Percutaneous PFO closure with device implantation has no impact on valve insufficiencies as determined by cardiac magnetic resonance imaging.
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